Thermo Fisher Scientific
Proteomics has seen many advances over the last decade from improvements in mass spectrometry instrumentation to an expansion of new workflows and applications. The promise of single-cell proteomics has been a topic frequently discussed over the last 10 years, with the hope it becomes a reality, and widely accessible to the scientific community.
Unlike single-cell genomics and transcriptomics, there is no amplification process in proteomics so there is no intrinsic workaround for the minute amounts of protein available as research material in a single cell. In addition for single-cell proteomics to be a viable alternative to single-cell genomics and transcriptomics, it needs to match these for throughput, cover the same order of magnitude in terms of the number of unique proteins detected and identified, and be easily implementable as part of a wide range of cellular assays.
Daniel Lopez-Ferrer, Senior Manager, Proteomics Marketing, Thermo Fisher Scientific
In his current role, Dani and his team are focused on the identification and development of new proteomics analytical tools and applications that bring broad benefits to the biosciences community. He has held positions as a Senior Scientist at Caprion Proteomics (CA, USA) and Pacific Northwest National Laboratory (WA, USA) developing technologies for high-throughput, large-scale proteomics projects. Dani has over 35 peer review papers and several patents.
Khatereh Motamedchaboki, Senior Vertical Marketing Specialist, Proteomics, Thermo Fisher Scientific
Khatereh works on cutting edge technologies and developing advanced proteomics workflows on new LC-MS product platforms. Prior to joining Thermo Fisher Scientific, she was the Director of the NCI-designated Cancer Center Proteomics Core at Sanford Burnham Preby’s Medical Discovery Institute, with over 30 peer review publications in proteomics field.
Please complete this form to receive your free copy.
* Required field